Clinical Trial

Melatonin & Metformin on Clinical & Biochemical Parameters in Insulin Resistant PCOS Compared to Metformin

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated March 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
Women with polycystic ovary syndrome with HOMA-IR \>2.6 fulfilling inclusion and exclusion criteria will be randomly allocated into two groups:experimental group: A (Melatonin 3mg and Metformin 500mg) and control group: B (Metformin 500mg). Each group will be contained 30 selected patients. Group B:Tab. Metformin (500mg) once daily for 7days followed by twice daily for next 7 days followed by thrice daily for next 10 weeks. Outcome variables will be measured after three months, will be meticulously recorded for analysis and comparison.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-13.
Trial Details
NCT Number NCT07307677
Lead Sponsor Mst.Sumyara Khatun
Collaborators: Bangladesh Medical University
Conditions PCOS(Insulin Resistant)
Enrollment 60 participants
Start Date 2025-03-11
Primary Completion 2026-03-10 (estimated)
Study Completion 2026-08-10 (estimated)
Updated on ClinicalTrials.gov 2026-01-07